SCHEMBL3883274

SCHEMBL3883274

O=C(O)CCc1ccc(OCC2CCCC2)c(-c2ccc3ccccc3c2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 8/20 0.55
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
S1PR1 P21453 1/20 0.45
CYP1A2 P05177 1/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
C5AR1 P21730 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
FFAR1 O14842 4/20 0.41
PTGER1 P34995 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
CASR P41180 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3888439 0.99 FFAR4 (0.54) FFAR4THRATHRBS1PR1CYP1A2
SCHEMBL3677382 0.94 CYP1A2 (0.53) FFAR4THRATHRBS1PR1CYP1A2
SCHEMBL3679667 0.91 FFAR4 (0.49) FFAR4THRATHRBS1PR1PPARD
SCHEMBL3682691 0.90 FFAR4 (0.48) FFAR4THRATHRBS1PR1C5AR1
SCHEMBL3690987 0.90 THRA (0.47) FFAR4THRATHRBS1PR1PPARD
SCHEMBL3881750 0.90 FFAR4 (0.53) FFAR4THRATHRBCYP1A2CCNC
SCHEMBL3885965 0.90 THRA (0.50) FFAR4THRATHRBS1PR1C5AR1
SCHEMBL7725119 0.89 THRA (0.52) FFAR4THRATHRBS1PR1C5AR1
SCHEMBL3881962 0.89 THRA (0.47) FFAR4THRATHRBS1PR1C5AR1
SCHEMBL3882697 0.89 THRA (0.49) FFAR4THRATHRBS1PR1PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885THRA 1720/4885THRB 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.